Advertisement

Metabolomics

, Volume 10, Issue 5, pp 1036–1041 | Cite as

1-Stearoylglycerol is associated with risk of prostate cancer: results from a serum metabolomic profiling analysis

  • Alison M. MondulEmail author
  • Steven C. Moore
  • Stephanie J. Weinstein
  • Satu Männistö
  • Joshua N. Sampson
  • Demetrius AlbanesEmail author
Short Communication

Abstract

Although prostate cancer is the most commonly diagnosed cancer among men in developed populations, recent recommendations against routine prostate-specific antigen screening have cast doubt on its utility for early detection. We compared the metabolomic profiles of prospectively collected fasting serum from 74 prostate cancer cases and 74 controls selected from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort of male smokers. Circulating 1-stearoylglycerol (1-SG, or 1-monostearin) was statistically significantly inversely associated with risk of prostate cancer after Bonferroni correction for multiple comparisons (i.e., 420 identified metabolites) (OR 0.34, 95 % CI 0.20–0.58, p 6.3 × 10−5). The magnitude of this association did not differ by disease aggressiveness and was observed for cases diagnosed up to 23 years after blood collection. Similar but somewhat weaker prostate cancer risk signals were also evident for glycerol and alpha-ketoglutarate. In this population, men with higher serum 1-SG were less likely to develop prostate cancer, supporting a role for dysregulation of lipid metabolism in this malignancy. Additional studies are needed to retest the association and to examine 1-SG for its potential as a prostate cancer early detection marker.

Keywords

Metabolomics Prostatic neoplasms Prospective study Nested case–control study Early detection Biomarker 

Notes

Acknowledgments

This work was supported by the Intramural Research Program of the National Cancer Institute at the National Institutes of Health (U.S. Public Health Service), and U.S. Public Health Service contracts N01-CN-45165, N01-RC-45035, N01-RC-37004, HHSN261201000006C, HHSN261200800001E.

Informed consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.

Supplementary material

11306_2014_643_MOESM1_ESM.pdf (665 kb)
Supplementary material 1 (PDF 665 kb)

References

  1. Beyoglu, D., et al. (2013). Tissue metabolomics of hepatocellular carcinoma: Tumor energy metabolism and the role of transcriptomic classification. Hepatology,. doi: 10.1002/hep.26350.PubMedCentralGoogle Scholar
  2. Brawley, O. W. (2012). Prostate cancer epidemiology in the United States. World Journal of Urology, 30, 195–200. doi: 10.1007/s00345-012-0824-2.CrossRefPubMedGoogle Scholar
  3. Dehaven, C. D., Evans, A. M., Dai, H., & Lawton, K. A. (2010). Organization of GC/MS and LC/MS metabolomics data into chemical libraries. Journal of Cheminformatics, 2, 9. doi: 10.1186/1758-2946-2-9.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Evans, A. M., DeHaven, C. D., Barrett, T., Mitchell, M., & Milgram, E. (2009). Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Analytical Chemistry, 81, 6656–6667. doi: 10.1021/ac901536h.CrossRefPubMedGoogle Scholar
  5. Lokhov, P. G., Dashtiev, M. I., Moshkovskii, S. A., & Archakov, A. I. (2010). Metabolite profiling of blood plasma of patients with prostate cancer. Metabolomics, 6, 156–163.CrossRefGoogle Scholar
  6. Menendez, J. A. (2010). Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: Molecular mechanisms and therapeutic perspectives. Biochimica et Biophysica Acta, 1801, 381–391. doi: 10.1016/j.bbalip.2009.09.005.CrossRefPubMedGoogle Scholar
  7. Moyer, V. A., & Force, U. S. P. S. T. (2012). Screening for prostate cancer: US preventive services task force recommendation statement. Annals of Internal Medicine, 157, 120–134. doi: 10.7326/0003-4819-157-2-201207170-00459.CrossRefPubMedGoogle Scholar
  8. Nicholson, J. K., & Lindon, J. C. (2008). Systems biology: Metabonomics. Nature, 455, 1054–1056. doi: 10.1038/4551054a.CrossRefPubMedGoogle Scholar
  9. Nomura, D. K., Long, J. Z., Niessen, S., Hoover, H. S., Ng, S. W., & Cravatt, B. F. (2010). Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell, 140, 49–61. doi: 10.1016/j.cell.2009.11.027.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Nomura, D. K., et al. (2011). Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chemistry & Biology, 18, 846–856. doi: 10.1016/j.chembiol.2011.05.009.CrossRefGoogle Scholar
  11. O’Connell, T. M. (2012). Recent advances in metabolomics in oncology. Bioanalysis, 4, 431–451. doi: 10.4155/bio.11.326.CrossRefPubMedGoogle Scholar
  12. Sampson, J. N., et al. (2013). Metabolomics in epidemiology: Sources of variability in metabolite measurements and implications. Cancer Epidemiology, Biomarkers, & Prevention in press,Google Scholar
  13. Sreekumar, A., et al. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 457, 910–914. doi: 10.1038/nature07762.CrossRefPubMedPubMedCentralGoogle Scholar
  14. The ATBC Cancer Prevention Study Group. (1994). The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Annals of Epidemiology, 4, 1–10.Google Scholar
  15. Thysell, E., et al. (2010). Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS ONE, 5, e14175. doi: 10.1371/journal.pone.0014175.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Trock, B. J. (2011). Application of metabolomics to prostate cancer. Urologic Oncology, 29, 572–581. doi: 10.1016/j.urolonc.2011.08.002.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York (outside the USA)  2014

Authors and Affiliations

  • Alison M. Mondul
    • 1
    Email author
  • Steven C. Moore
    • 1
  • Stephanie J. Weinstein
    • 1
  • Satu Männistö
    • 2
  • Joshua N. Sampson
    • 3
  • Demetrius Albanes
    • 1
    Email author
  1. 1.Nutritional Epidemiology Branch, Division of Cancer Epidemiology and GeneticsNational Cancer Institute, NIH, Department of Health and Human ServicesBethesdaUSA
  2. 2.Department of Chronic Disease PreventionNational Institute for Health and WelfareHelsinkiFinland
  3. 3.Biostatistics Branch, Division of Cancer Epidemiology and GeneticsNational Cancer Institute, NIH, Department of Health and Human ServicesBethesdaUSA

Personalised recommendations